What it's for (Indications)
- Piroxicam beta cyclodextrin is used for pain and inflammation associated with inflammatory diseases including rheumatic pain, osteoarthritis, and ankylosing spondylitis.
- It is also indicated for postoperative pain, traumatic pain, painful period cramps, headache (including migraine), and toothache.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Piroxicam beta cyclodextrin is formulated to enhance the solubility and absorption of piroxicam, allowing for a more rapid onset of action compared to conventional piroxicam. The typical adult dosage for acute conditions, such as acute musculoskeletal disorders or acute gout, is generally 20 mg (equivalent to 20 mg of piroxicam) administered orally once daily. For chronic inflammatory conditions like osteoarthritis or rheumatoid arthritis, a maintenance dose of 20 mg once daily is commonly prescribed. However, the prescriber may adjust the dosage based on the patient's individual response, disease severity, and tolerability. It is crucial to use the lowest effective dose for the shortest possible duration to mitigate potential risks associated with NSAID therapy, particularly gastrointestinal and cardiovascular adverse events. Dosing in pediatric patients is not routinely recommended, and specific geriatric considerations or dose adjustments may be necessary due to increased susceptibility to adverse effects and altered pharmacokinetic profiles. Always adhere to the prescribing information provided by the manufacturer and the guidance of a qualified healthcare professional. |
Safety & Warnings
Common Side Effects
- Side effects include gastrointestinal disturbances, skin reactions, edema (swelling), brain effects, malaise (feeling of discomfort), and tinnitus (ringing in ears).
Serious Warnings
- Black Box Warning: Piroxicam beta cyclodextrin, like other non-steroidal anti-inflammatory drugs (NSAIDs), carries significant risks that warrant careful consideration and are highlighted in a Black Box Warning by regulatory agencies. This medication increases the risk of serious, and potentially fatal, cardiovascular thrombotic events, including myocardial infarction and stroke. This risk may occur early in treatment and may increase with duration of use. Patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Furthermore, piroxicam beta cyclodextrin significantly elevates the risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can also be fatal. These serious GI events can occur at any time during use, often without warning symptoms. Elderly patients and those with a history of peptic ulcer disease or GI bleeding are at a particularly high risk. Piroxicam beta cyclodextrin is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery due to the increased risk of cardiovascular events.
- Caution is advised for older people, children younger than 12 years, and patients with infections, allergies, asthma, bleeding disorders, or hypertension.
- Use with caution in patients with inadequate kidney, liver, or heart function.
- Individuals with liver or kidney diseases should consult their doctor before use.
- Patients should avoid driving or operating machinery if experiencing dizziness, drowsiness, headache, or hypotension as adverse effects.
- Alcohol consumption is not recommended during treatment.
How it Works (Mechanism of Action)
Piroxicam beta cyclodextrin exerts its therapeutic effects primarily through the non-selective inhibition of cyclooxygenase (COX) enzymes, specifically both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This enzymatic inhibition leads to a significant reduction in the biosynthesis of prostaglandins from arachidonic acid, which are key lipid mediators of inflammation, pain, and fever. By decreasing prostaglandin production, piroxicam effectively alleviates inflammatory responses, reduces pain perception (analgesic effect), and helps to lower elevated body temperature (antipyretic effect). The inclusion of beta cyclodextrin in this pharmaceutical formulation serves as a complexing agent that significantly improves the aqueous solubility and dissolution rate of piroxicam. This enhanced solubility facilitates faster absorption from the gastrointestinal tract, leading to quicker attainment of therapeutic plasma concentrations and, consequently, a more rapid onset of analgesic and anti-inflammatory action compared to conventional piroxicam formulations. The improved pharmacokinetic profile potentially contributes to more efficient and prompt symptomatic relief for patients, particularly in acute pain and inflammatory conditions.
Commercial Brands (Alternatives)
No other brands found for this formula.